Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 10, 2022

Anitoa Systems introduces new kits for detecting Covid variant mutations

Anitoa’s solution avoids the complex process of packing and shipping patient samples to a central laboratory.

Anitoa Systems has expanded its SARS-CoV-2 rapid nucleic acid test portfolio with the launch of two new kits to detect Delta and Omicron mutations.

The two kits include the research use only (RUO) SARS-CoV-2, Delta and Omicron kit, as well as the CE-IVD certified SARS-CoV-2 and Delta variant kit.

To test SARS-CoV-2 as well as its variants, the company integrates an in-house portable real-time polymerase chain reaction (qPCR) instrument, named Maverick, and its reverse transcription qPCR (RT-qPCR) reagent.

Anitoa Systems stated that the solution helps avoid the complex process of packing and shipping patient samples to a central laboratory along with the additional steps needed before running RT-qPCR.

According to the company, this helps to reduce cross-contamination risks and saves time.

By avoiding the degradation of viral RNAs that occurs while samples are being shipped, Anitoa’s portable device also reduces false-negative readings and provides more accurate results.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

The solution allows patient samples, such as nasal or throat swabs, to be directly applied to the portable instrument on-site and removes the need to freeze, transport and thaw samples in a lab.

Anitoa Systems CEO Dr Zhimin Ding said: “As a key supplier of equipment and materials for detecting SAR-Cov-2, Anitoa is closely monitoring all current and emerging variants of this deadly virus to ensure that our test solutions are relevant to the need of the people combating this disease.”

The Maverick RT-qPCR device detects multiple gene targets in a single sample with a four-plex optical multiplexing subsystem. It takes approximately 45 minutes to deliver results.

Recently, Quidel confirmed that its Sofia SARS Antigen FIA and QuickVue At-Home OTC Covid-19 Test has the capability to detect new and emerging Covid-19 variants, such as Omicron.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU